New consumer friendly packaging for Equitop Myoplast

Boehringer Ingelheim has launched eye-catching new packaging for Equitop Myoplast, its leading supplement that supports lean muscle growth in horses.

The new packaging has been designed to clearly communicate the benefits of the product to horse owners. It features a ‘Vet Endorsed’ badge to emphasise its veterinary heritage, together with an easy-to-read product description to highlight that the product supports muscle development in horses. This includes “What is Equitop Myoplast?”, “When to use Equitop Myoplast?” and “How does Equitop Myoplast support my horse?” and it also has details on feeding recommendations, feeding periods and storage.

“We have launched new packaging for Equitop Myoplast to clearly communicate the benefits of the product to horse owners,” comments, Liz Barrett, equine business head at Boehringer Ingelheim.

Equitop Myoplast contains a unique blend of 18 key amino acids derived from spirulina. These amino acids are the building blocks of healthy muscle tissue, so it makes sense to ensure that they are present in an easily digestible form in a horse’s diet.

Equitop Myoplast provides support for horses in training and competition, as well as young, developing horses and older horses that lose condition easily. In particular, many veterinary surgeons recommend feeding Equitop Myoplast during the rehabilitation period to support recovery.

Leading riders use Equitop Myoplast including international showjumpers Scott Brash, William Whitaker, Trevor Breen and Joe Davison. It is also a favourite among dressage riders and trainers including Richard Davison.

Equitop Myoplast is available as tasty pearl granules and is free of prohibited substances. It comes in a 1.5kg tub and can be fed separately or mixed with feed. Horses weighing less than 500kg should be fed one scoop (25g) per day, while larger horses should receive two scoops (50g). Boehringer Ingelheim recommends that Equitop Myoplast is fed for at least two months.
Advice on the use of Equitop Myoplast or other products should be sought from a veterinary surgeon. Further information available from Boehringer Ingelheim Ltd,

About Boehringer Ingelheim
Boehringer Ingelheim is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates presently with a total of some 50,000 employees worldwide.
The focus of the family-owned company, founded in 1885, is on researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.
Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects through, for example, the initiative “Making More Health” while also caring for employees. Respect, equal opportunity and reconciling career and family form the foundation of mutual cooperation. The company also focuses on environmental protection and sustainability in everything it does.
In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of net sales